White Ointment JP

White ointment with a slight characteristic odour.

References: [1]

Lipophilic ointment base. JP specifies it as the base of Zinc Oxide Ointment. This monograph does not provide an independent therapeutic indication or dose.

References: [1]

White appearance, slight characteristic odour and viscosity suitable for cutaneous application under JP 11-4. No numerical viscosity limit, pH or product-specific assay is given.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

Exact identities: Λευκός κηρός μελισσών / White beeswax; Σεσκιελαϊκός εστέρας σορβιτάνης / Sorbitan sesquioleate; Λευκή βαζελίνη / White petrolatum. Use pharmacopoeial raw materials of the referenced edition, with CoA verification. Do not arbitrarily change salt, hydration state or strength. Record the actual q.s. amount in the batch.

References: [1]

JP provides no specific numerical room limits for this formula. Define a local SOP covering suitable clean conditions, temperature control and contamination prevention. This is an editorial checklist.

References: [1] · [2]

Clean protective clothing and head covering under AEMPS PN/L/PG/002/00. Use suitable gloves where contact is possible and respiratory/eye protection where powder handling requires it. Exact glove material, ventilation and respiratory protection must follow the SDS and local exposure assessment.

References: [4]

Base without a medicinal active. Local assessment includes hot melt, burns, ingredient allergy and contamination risk. No potent-drug classification has been established.

References: [1]

The specific monograph provides no finished-product beyond-use period/BUD. No duration is assigned by assumption. Suitable stability evidence and responsible-pharmacist approval are required before release.

References: [1]

No separate compound base is required in the explicit formula.

References: [1]

Balance with suitable resolution, mortar/spatula, suitable mixing vessels and final container. Add volumetric equipment for mL, a controlled water bath where melting is specified and a suitable filter where required. Analytical equipment follows the QC methods.

References: [1] · [2]

1. Weigh the ingredients; theoretical white petrolatum is 930 g.
2. Melt and mix the lipophilic base components by controlled warming under JP 11-4.
3. Mix/knead until homogeneous. The local SOP must define the exact temperature, time and mixing speed; the monograph does not provide them.

References: [1] · [2]

Original bilingual rendering of the formula and specifications. This base differs from Simple Ointment BP, USP White Ointment and plain petrolatum.

References: [1]

Tight container. No specific container material is prescribed.

References: [1]

White Ointment JP
Quantity: _____ · Batch: _____ · Prepared: _____ · Use by: _____
External use only. Storage: Keep tightly closed. No specific temperature or light protection is prescribed for the finished product.
Patient/directions or laboratory use: _____ · Pharmacy/telephone: _____
Specimen for pharmacist adaptation; not a final approved label.

References: [1]

Check appearance, odour and suitable consistency under the monograph/JP 11-4. Final mass and homogeneity are proposed local process checks. They do not replace overall JP conformity or establish a beyond-use period.

References: [1] · [2]

Keep tightly closed. No specific temperature or light protection is prescribed for the finished product.

References: [1]

Intended for pharmaceutical use as a base. Adding an active requires compatibility assessment and separate evidence for the finished preparation.

References: [1]